RxDoctor Payments Data

Judith Tiongco, MD

Internal Medicine · West Orange, NJNPI 1669591491

Payments from drug & device makers

$1,502in general payments, 2019–2025

Across 77 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$239
  • Cleerly, Inc.$217
  • Otsuka America Pharmaceutical, Inc.$144
  • Exact Sciences$127
  • Eisai Inc.$102
  • Abbott$99
  • plus $573 from 16 others

What the payments were for

  • Food & beverage$1,502100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,502 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$79,432
Medicare patients
298
Services billed
1,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$26,022
JardianceEmpagliflozin15$15,457
LexaproEscitalopram Oxalate11$7,052
SynthroidLevothyroxine Sodium28$2,660
Atorvastatin Calcium341$2,655
Ezetimibe53$2,095
Rosuvastatin Calcium152$2,067
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,298
Amlodipine Besylate173$1,276
Gabapentin69$1,230
Metoprolol Succinate84$1,118
Duloxetine Hcl43$1,073
Levothyroxine Sodium120$1,070
Losartan Potassium94$1,053
Omeprazole39$961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$84$26,02221 claims
AbbVieLexapro, Synthroid$49$9,71239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →